New Update: Candid Therapeutics & EpimAb Partner to Develop T-Cell Engagers for Autoimmune Diseases. Learn more here.

macls_home_heroStill.png

Mirae Asset believes in changing the future through investment

Mirae Asset Financial Group:

  • Total Equity Capital
  • Total Assets Under Management
  • Global Footprint
  • Total AUM for Biotech
  • Total Employees

As of September 30, 2024 – Mirae Asset Financial Group

Mirae Asset Capital Life Science was formed in 2023 as a joint venture between Mirae Asset Capital and Mirae Asset Global Investments

It is the first and only U.S. affiliate of Mirae Asset dedicated to investment in Life Science

First Fund Stats:

  • Scope
  • Focus
  • Check Size
  • Geographic Focus
  • Follow-on Support

A differentiated investment strategy rooted in drug development, clinical data, and market dynamics

Handless Clock

We invest in companies prioritizing the delivery of safe and effective treatments, as fast as possible, to patients who need them most

Accent Therapeutics

Scientists, company builders, and operators who get it